Inflammatory pathways – indirect modulation

Inflammatory pathways – indirect modulation refers to a broad therapeutic strategy rather than a single molecular target. It encompasses the down-regulation of pro-inflammatory responses through secondary mechanisms, such as the inhibition of upstream transcription factors like NF-kappaB, the activation of resolving lipid mediators, or the modulation of the microbiome to reduce systemic endotoxemia (Source: Nature Reviews Drug Discovery, 2020). Unlike direct inhibitors that bind to specific cytokines or their receptors, indirect modulators often have pleiotropic effects, influencing multiple points within the inflammatory cascade to restore homeostasis (Source: Frontiers in Pharmacology, 2021). This approach is frequently utilized in the treatment of chronic inflammatory conditions where targeting a single cytokine may be insufficient due to pathway redundancy. Because this term describes a functional outcome or a class of mechanisms rather than a specific protein, it is considered a descriptive category in pharmacological databases rather than a canonical drug target (Source: IUPHAR/BPS Guide to Pharmacology).

Other names

Indirect inflammatory modulationModulation of inflammatory mediatorsSecondary anti-inflammatory effects

Indirect modulation involves affecting inflammatory outcomes without binding directly to a primary inflammatory receptor or enzyme; instead, it occurs through the regulation of upstream signaling cascades, epigenetic modifications, or the stabilization of endogenous anti-inflammatory mediators.